RT Journal Article
SR Electronic
T1 Repurposing Domperidone in Secondary Progressive Multiple Sclerosis
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP e2313
OP e2322
DO 10.1212/WNL.0000000000011863
VO 96
IS 18
A1 Marcus W. Koch
A1 Kayla Sage
A1 Sharanjit Kaur
A1 Janet Kim
A1 Graziela Cerchiaro
A1 V. Wee Yong
A1 Gary R. Cutter
A1 Luanne M. Metz
YR 2021
UL http://n.neurology.org/content/96/18/e2313.abstract
AB Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.Methods We enrolled patients in an open-label, Simon 2-stage, single-center, phase 2, single-arm futility trial at the Calgary Multiple Sclerosis Clinic if they met the following criteria: age of 18 to 60 years, SPMS, screening Expanded Disability Status Scale score of 4.0 to 6.5, and screening timed 25-ft walk (T25FW) of ≥9 seconds. Patients received domperidone 10 mg 4 times daily for 1 year. The primary outcome was worsening of disability, defined as worsening of the T25FW performance by ≥20% at 12 months compared to baseline. This trial is registered with ClinicalTrials.gov (NCT02308137).Results Between February 13, 2015, and January 3, 2020, 110 patients were screened, 81 received treatment, and 64 completed follow-up, of whom 62 were analyzed. The study did not meet its primary endpoint: 22 of 62 (35%) patients experienced significant worsening of disability, which is close to the expected proportion of 40% and above the predefined futility threshold. Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, which may warrant further investigation. Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients.Conclusions Domperidone treatment could not reject futility in reducing disability progression in SPMS. The Simon 2-stage trial model may be a useful model for phase 2 studies in progressive MS.Trial Registration Information ClinicalTrials.gov Identifier: NCT02308137.Classification of Evidence This study provides Class III evidence that in individuals with SPMS participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.ASCEND=A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis; CHREB=Conjoint Health Research Ethics Board; EDSS=Expanded Disability Status Scale; MFIS=Modified Fatigue Impact Scale; MS=multiple sclerosis; MSQOL-54=MS Related Quality of Life Scale 54-item version; 9HPT=9-hole peg test; QTc=frequency-corrected QT interval; RCT=randomized controlled trial; RRMS=relapsing-remitting MS; SDMT=Symbol Digit Modalities Test; SPMS=secondary progressive multiple sclerosis; T25FW=timed 25-ft walk